Resultats de la cerca - Chris H. Takimoto

  • Mostrar 1 - 20 resultats de 20
Refinar resultats
  1. 1
    Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

    Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes per Ricardo M. Attar, Chris H. Takimoto, Marco M. Gottardis

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice

    Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice per Minalini Lakshman, Li Xu, Vijayalakshmi Ananthanarayanan, J. C. Cooper, Chris H. Takimoto, Irene Helenowski, Jill C. Pelling, Raymond C. Bergan

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Identification of an RNA binding site for human thymidylate synthase.

    Identification of an RNA binding site for human thymidylate synthase. per Edward Chu, Donna Voeller, David M. Koeller, J C Drake, Chris H. Takimoto, Gladys F. Maley, Frank Maley, Carmen J. Allegra

    Publicat 1993
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

    Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer per Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target

    The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target per Chris H. Takimoto, Mark P. Chao, C. Parker Gibbs, Mark McCamish, J. Liu, J.Y. Chen, Ravindra Majeti, Irving L. Weissman

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors

    A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors per Muhammad Wasif Saif, Chris H. Takimoto, Monica Mita, Udai Banerji, Nicole Lamanna, Januario E. Castro, Susan O'Brien, Christopher Stogard, Daniel D. Von Hoff

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

    Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies per Mark P. Chao, Chris H. Takimoto, Dong Dong Feng, Kelly M. McKenna, Phung Gip, Jie Liu, Jens-Peter Volkmer, Irving L. Weissman, Ravindra Majeti

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

    An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors per María L. Amador, Darin Oppenheimer, Sofía Perea, Anirban Maitra, G. Cusati, Christi Iacobuzio-Donahue, Sharyn D. Baker, Raheela Ashfaq, Chris H. Takimoto, Arlene A. Forastiere, Manuel Hidalgo

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

    Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin per Anthony W. Tolcher, Alain C. Mita, Lionel D. Lewis, Christopher R. Garrett, Elizabeth Till, Adil Daud, Amita Patnaik, K. Papadopoulos, Chris H. Takimoto, Pamela Bartels, Anne Keating, Scott Antonia

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

    A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies per Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy Chu, Nancy Wong, Christopher DesJardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

    Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-643... per Patricia LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, S. Percy Ivy

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

    Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia per Dongdong Feng, Phung Gip, Kelly M. McKenna, Feifei Zhao, Ofelia Mata, Timothy Choi, Jiaqi Duan, Kavitha Sompalli, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, James Y. Chen, Jie Liu, Jens-Peter Volkmer

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

    Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Org... per Ramesh K. Ramanathan, Merrill J. Egorin, Chris H. Takimoto, Scot C. Remick, James H. Doroshow, Patricia LoRusso, Daniel Mulkerin, Jean L. Grem, Anne Hamilton, Anthony J. Murgo, Douglas M. Potter, Chandra P. Belani, Michael Hayes, Bin Peng, S. Percy Ivy

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

    Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function per Chris H. Takimoto, Martin A. Graham, G. Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

    Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab per Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Mark Basik, Christopher Harbison, Shujian Wu, Tai W. Wong, Xin Huang, Chris H. Takimoto, Andrew K. Godwin, Benjamin Tan, Smitha Krishnamurthi, Howard A. Burris, Elizabeth Poplin, Manuel Hidalgo, José Baselga, Edwin Clark, David J. Mauro

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

    Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function per Alain C. Mita, Christopher J. Sweeney, Sharyn D. Baker, Andrew Goetz, Lisa A. Hammond, Amita Patnaik, Anthony W. Tolcher, Miguel A. Villalona‐Calero, Alan Sandler, Tuhin K. Chaudhuri, Kathleen Molpus, Jane E. Latz, Lorinda Simms, Ajai K. Chaudhary, Robert D. Johnson, Eric K. Rowinsky, Chris H. Takimoto

    Publicat 2006
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

    Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas per Robert G. Maki, David R. D’Adamo, Mary Louise Keohan, Michael Saulle, Scott M. Schuetze, Samir D. Undevia, Michael B. Livingston, Matthew M. Cooney, Martee L. Hensley, Monica Mita, Chris H. Takimoto, Andrew S. Kraft, Anthony Elias, Bruce Brockstein, Nathalie E. Blachère, Mark Edgar, Lawrence H. Schwartz, Li-Xuan Qin, Cristina R. Antonescu, Gary K. Schwartz

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

    CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma per Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, Andres Forero, Nancy L. Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann S. LaCasce, Graham P. Collins, Thu Ha Tran, Judith Lynn, James Y. Chen, Jens-Peter Volkmer, Balaji Agoram, Jie Huang, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Mark P. Chao, Sonali M. Smith

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers per Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik, Sumit Shah, Sreenivasa R Chandana, Drew Rasco, A. Dimitrios Colevas, Timothy J. O’Rourke, Sujata Narayanan, Kyriakos P. Papadopoulos, George A. Fisher, Víctor M. Villalobos, Susan Prohaska, Maureen Howard, Muralidhar Beeram, Mark P. Chao, Balaji Agoram, James Y. Chen, Jie Huang, Matthew Axt, Jie Liu, Jens-Peter Volkmer, Ravindra Majeti, Irving L. Weissman, Chris H. Takimoto, Dana Supan, Heather A. Wakelee, Rhonda Aoki, Mark D. Pegram, Sukhmani K. Padda

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

    Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols per Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, Carlo Bifulco, Christian M. Capitini, Laura Q.M. Chow, Anthony R. Cillo, Deborah Collyar, Leslie Cope, Julie S. Deutsch, Genia Dubrovsky, Sacha Gnjatic, Denise Goh, Susan Halabi, Gary Kohanbash, Holden T. Maecker, Saman Maleki Vareki, Sarah Mullin, Barbara Seliger, Janis M. Taube, Wim Vos, Joe Yeong, Kristin G. Anderson, Tullia C. Bruno, Codruța Chiuzan, Iván Díaz-Padilla, Elizabeth Garrett‐Mayer, Isabella C. Glitza Oliva, Paola Grandi, Elizabeth G. Hill, Brian P. Hobbs, Yana G. Najjar, Phyllis Pettit Nassi, Virgil Simons, Sumit K. Subudhi, Ryan J. Sullivan, Chris H. Takimoto

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: